Since the outbreak of the epidemic, COVID-19 vaccine and COVID-19 specific drugs have been an important means of epidemic prevention, and they have been highly anticipated by the outside world. Therefore, many pharmaceutical companies are engaged in research and development, and the epidemic has been going on for three years, and research and development has gradually achieved results. Everyone is full of expectation and curiosity.
Recently, a company called Junshi Bio has attracted everyone's attention, and Weibo has posted a hot search for news about their new drug coming on the market. At the same time, Yang Ma also reported the matter. As early as a year ago, Junshi Bio announced that it had reached a cooperation agreement with Wangshan Wangshui to jointly develop the domestic COVID-19 therapeutic drug VV116. A year later, they finally got the result. On June 24, 222, CCTV2 reported "On-time Finance". Domestic oral liquid VV116, an anti-COVID-19 drug, entered the third phase of clinical trials and formally submitted its application for listing to the State Food and Drug Administration. VV116 is expected to become the first COVID-19 specific drug in China.